Zelgor 250MG Tablet

• Prostate Cancer

Like any other anticancer medicine, Zelgor 250MG Tablet also shows some side effects, which vary from one person to another according to various health factors. Most of them are mild, and some are serious enough to need immediate medical attention.
Some common side effects include:

• Diarrhea
• High blood pressure
• Cough
• Joint swelling
• Nausea
• Hot flashes
• Headache
• Increased glucose level in the blood
• Edema (swelling)
• Vomiting
• Decreased potassium level in the blood
• Fatigue
• Anemia (low number of red blood cells)
• Urinary tract infection

Seek medical attention in case of any unusual or severe side effects immediately.

Take Zelgor 250MG Tablet in the dosage and duration exactly as prescribed by the doctor. The medicine should be taken orally on an empty stomach or can be consumed one hour before or two hours after a meal. In case of an overdose, contact your doctor immediately.

• Zelgor 250MG Tablet is an anticancer medicine prescribed to treat prostate cancer. Abiraterone acetate is the active ingredient of the medicine. I
• t works by blocking the action of CYP17 enzyme to stop the production of male hormones that are responsible for prostate cancer. In this way, it slows down or stops the uncontrolled growth of cancer cells effectively.
  
  

• Rehman, Y., & Rosenberg, J. E. (2012). Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer. Drug design, development and therapy, 13-18. https://pubmed.ncbi.nlm.nih.gov/22291466/
• Ryan, C. J., & Cheng, M. L. (2013). Abiraterone acetate for the treatment of prostate cancer. Expert opinion on pharmacotherapy, 14(1), 91-96. https://pubmed.ncbi.nlm.nih.gov/23199349/
• Sonpavde, G., Attard, G., Bellmunt, J., Mason, M. D., Malavaud, B., Tombal, B., & Sternberg, C. N. (2011). The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature. European urology, 60(2), 270-278. https://hero.epa.gov/reference/7353296/
• Attard, G., Reid, A. H., A'Hern, R., Parker, C., Oommen, N. B., Folkerd, E., ... & de Bono, J. S. (2009). Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. Journal of clinical oncology, 27(23), 3742-3748. https://pubmed.ncbi.nlm.nih.gov/19470933/
• Scott, L. J. (2017). Abiraterone acetate: a review in metastatic castration-resistant prostate cancer. Drugs, 77(14), 1565-1576. https://pubmed.ncbi.nlm.nih.gov/28819727/
• Thakur, A., Roy, A., Ghosh, A., Chhabra, M., & Banerjee, S. (2018). Abiraterone acetate in the treatment of prostate cancer. Biomedicine & Pharmacotherapy, 101, 211-218. https://pubmed.ncbi.nlm.nih.gov/29494958/